Last reviewed · How we verify
Mifurol (CARMOFUR)
Mifurol (generic name: CARMOFUR) is a carmofur drug. It is currently in Phase 2 development for Malignant tumor of colon.
Mifurol works by inhibiting the enzyme acid ceramidase, which plays a role in the development and progression of cancer cells.
Mifurol, also known as Carmofur, is a small molecule drug that targets acid ceramidase. It is classified as a carmofur and is used to treat malignant tumors of the colon. The commercial status of Mifurol is unclear, and it is not known if it is patented or available as a generic medication. As a cancer treatment, Mifurol's safety considerations are critical, but specific details are not available. Further research is needed to understand its pharmacokinetic properties and clinical use.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CARMOFUR |
|---|---|
| Drug class | carmofur |
| Target | Acid ceramidase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Think of cancer cells like a city with a strong wall. Acid ceramidase is like a key that helps the cancer cells build and repair their wall, making them stronger. Mifurol blocks this key, making it harder for the cancer cells to grow and spread.
Approved indications
- Malignant tumor of colon
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mifurol CI brief — competitive landscape report
- Mifurol updates RSS · CI watch RSS
Frequently asked questions about Mifurol
What is Mifurol?
How does Mifurol work?
What is Mifurol used for?
What is the generic name of Mifurol?
What drug class is Mifurol in?
What development phase is Mifurol in?
What does Mifurol target?
Related
- Drug class: All carmofur drugs
- Target: All drugs targeting Acid ceramidase
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Malignant tumor of colon
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing